Drug Discovery World

NOVEMBER 2, 2023

Fiona Elwood will explore some of the latest advancements in Alzheimer’s disease research, which includes data science techniques, digital health tools and novel biomarkers, while highlighting the unmet needs in developing treatments for Alzheimer’s disease that target the underlying causes of the condition.

Reagent 52

Reagent Drugs Development Medicine 52

Drug Discovery World

OCTOBER 26, 2023

Fiona Elwood will explore some of the latest advancements in Alzheimer’s disease research, which includes data science techniques, digital health tools and novel biomarkers, while highlighting the unmet needs in developing treatments for Alzheimer’s disease that target the underlying causes of the condition.

Reagent 52

Reagent Drugs Development Medicine 52

Drug Discovery World

OCTOBER 19, 2023

Fiona Elwood will explore some of the latest advancements in Alzheimer’s disease research, which includes data science techniques, digital health tools and novel biomarkers, while highlighting the unmet needs in developing treatments for Alzheimer’s disease that target the underlying causes of the condition.

Reagent 52

Reagent Drugs Development Medicine 52

Drug Discovery World

OCTOBER 12, 2023

Fiona Elwood will explore some of the latest advancements in Alzheimer’s disease research, which includes data science techniques, digital health tools and novel biomarkers, while highlighting the unmet needs in developing treatments for Alzheimer’s disease that target the underlying causes of the condition.

Reagent 52

Reagent Drugs Development Medicine 52

Pharmaceutical Technology

SEPTEMBER 14, 2022

Emerging technologies such as 3D printing and bioprinting, electrospinning, electrospraying, microfluidics, nanofluidics, microelectromechanical, and bio-electromechanical systems are being utilised to prepare systems for the delivery of personalised medicine, meeting patient’s needs, and developing old drugs with new processes.

Protein 130

Protein Marketing Manufacturing Reagent 130

Pharmaceutical Technology

FEBRUARY 3, 2023

The field of genomic medicine has reached a true turning point. Researchers have relentlessly worked through the barriers to create lifechanging treatments for patients in need. “As For example, researchers have developed a two-plasmid cotransfection system.

Genome 244

Genome Genomics Medicine Gene Therapy 244

Roots Analysis

FEBRUARY 21, 2022

Advancement in DNA sequencing technologies have resulted in noteworthy developments in various healthcare-related research fields, such as diagnostics and personalized medicine. Moreover, the manual protocols require extensive manipulation, costly reagents and long duration of skilled genomic library production.

Marketing 52

Marketing Gene Sequencing DNA Genome 52

pharmaphorum

JANUARY 25, 2022

Canadian firm BenchSci has secured around $50 million in third-round financing that will be used to speed up the adoption of its artificial intelligence-powered platform for biomedical research internationally. The company is tapping into longstanding concerns in the life science industry about R&D productivity.

Life Science 52

Life Science Pharma Companies Reagent Scientist 52

Roots Analysis

AUGUST 16, 2023

mRNA has completely revolutionized the field of medicine and significantly influenced the study and treatment of human diseases. The success of COVID-19 vaccines paved the path for mRNA-based drug products. Safety, efficacy and rapid production of mRNA drives the interest in this domain.

Contract Manufacturing 52

Contract Manufacturing Manufacturing Marketing RNA 52

pharmaphorum

AUGUST 16, 2020

There are profound changes taking place in the area of life science research and development,” stated Swittons CEO and Founder Anupam Nandwana. Reorder reagents. Built on an agile technology platform, Swittons devices are easy to deploy within pharmaceutical laboratories of all types. Notify of spill/cleaning needed. Open SOP software.

Life Science 129

Life Science Reagent Scientist Clinical Trials 129

Camargo

MAY 2, 2021

Advances in scientific knowledge and growth in the cell and gene therapy space have led to a new and exciting era of medicine for patients, as well as a new motivation for regulators to provide clear, efficient pathways for product developers. Note: Some medicines are in more than one category.

Gene Therapy 155

Gene Therapy Gene Packaging Packaging 155

The Pharma Data

JANUARY 24, 2021

“Adding Chris to our leadership team will bolster our preclinical pipeline and translational research capabilities to accelerate development of the company’s cell therapy candidates from discovery into clinical application.” at Sunnybrook Research Institute and Peter Zandstra , Ph.D., .

Engineer 52

Engineer Gene Editing Genome Genomics 52

Advarra

NOVEMBER 29, 2022

The field of cell and gene therapies (CGT) is constantly evolving, and there has been significant progress in this area of research. However, despite the promise of these therapies, the regulations governing them lag the science, which in turn hinders the clinical translation of these novel medicines.

Gene Therapy 52

Gene Therapy Gene Production Clinical Trials 52

The Pharma Data

SEPTEMBER 8, 2021

The acquisition enables Roche to further expand the portfolio of currently over 45 CE-IVD assays and more than 100 research use assays on Roche`s LightCycler PCR instruments. TIB Molbiol is a biotech company that has supplied the global market with reagents for research and medical diagnostics for over 30 years.

Genotype 52

Genotype Reagent Genetics Research 52

The Pharma Data

MARCH 16, 2022

Roche and its subsidiary, Tib Molbiol, confirm that it has tests for research use that identify the SARS-CoV-2 subvariants of concern, Omicron: BA.1, It’s critical to quickly and accurately identify variants to inform ongoing research – including the ongoing development of therapeutics and vaccines. 3 and Delta.

In-Vitro 52

In-Vitro Genotype Reagent Protein 52

The Pharma Data

MAY 17, 2021

Academic centers should establish risk management programs to successfully commercialize cell and gene therapy products and to be a viable partner with contract research organizations (CROs) and manufacturers in developing these therapies. .

Development 52

Development Gene Therapy Manufacturing Gene 52

XTalks

OCTOBER 19, 2023

They typically work in the biotechnology, pharmaceutical and diagnostic sectors as well as in academic research, having pivotal roles in the early stages of drug discovery, research and diagnostic tool development by creating reliable tests that can provide essential data on biological samples.

Scientist 59

Scientist Development Research Compliance 59

The Pharma Data

OCTOBER 19, 2020

DB ( Becton, Dickinson and Company ) received a CE mark for its BD Multitest 6-Color TBNK Reagent with BD Trucount Tubes for assessing immune function in COVID-19 patients. Army Medical Research and Development (USAMRDC ) initiated a Phase I clinical trial of its novel vaccine against COVID-19. Please read more here. .

Vaccination 52

Vaccination Vaccine Trials Clinical Trials 52

Drug Discovery World

APRIL 3, 2023

DS: What motivated you and Dr David Bunka, CTO, to create Aptamer and did you imagine you would one day be operating on such a global scale?    AT : We initially met at the University of Leeds, where David was a post-doctoral researcher studying aptamers, and I was completing my PhD.

Antibody 52

Antibody Gene Therapy Gene In-Vitro 52

The Pharma Data

MAY 15, 2023

Huebscher , non-executive board member in companies, institutions and former CEO of Solvias Group, a Swiss contract research firm, which she led between 2014 and 2021. She is also a board member at BBI Solutions, a UK based diagnostic reagents and a Novo Holdings company. The new board members are: Dr. Karen J. Source link: [link]

Sales 40

Sales Production Doctors Doctor 40

Drug Discovery World

FEBRUARY 15, 2023

The first such research dates back to 1891, when William Coley attempted to inject heat-inactivated bacteria to treat osteosarcoma. This is an exciting field of cancer research which involves harnessing the body’s own immune system to target cancerous cells.

Research 52

Research In-Vitro In-Vivo Development 52

The Pharma Data

JULY 11, 2021

Hereditary angioedema is a lifelong condition and research shows that concerns about another attack can limit the way patients lead their lives,” said Prof. Traceability: In order to improve the traceability of biological medicinal products, the name and the batch number of the administered product should be clearly recorded.

Allergies 52

Allergies Antibody Recombinant DNA Technology Production 52

Drug Discovery World

DECEMBER 28, 2022

The Breath Biopsy VOC Atlas is a catalogue of validated and quantitated volatile organic compounds (VOCs) found on breath, designed to assist in the development of biomarkers and precision medicines. . Gyrolab Human Cytokine Kit Reagents are the first in a range of new biomarker kits from Gyros Protein Technologies. .

Production 97

Production Reagent Drugs Life Science 97

Pharmaceutical Technology

FEBRUARY 15, 2023

RNA has the potential to underpin breakthrough treatments for a wide variety of diseases, including many cancers, and transform medicine as we know it. Outlook The era of mRNA-based genomic medicines is on the horizon. But the mRNA technology is not yet mature and there are no standardised manufacturing protocols yet.

Bioassay 130

Bioassay Development RNA Drugs 130

The Pharma Data

MARCH 20, 2021

The Challenge: The demands of many labs simultaneously beginning COVID-19 screening programs are leading to a scarcity of resources like pipette tips and reagents. Medicine in Oxford, Biogazelle, a biotechnology company in Ghent, and the Centre For Proteome Research at the University of Liverpool. delays where reagents are in.

Reagent 52

Reagent RNA Bioinformatics Medicine 52

Drug Discovery World

OCTOBER 21, 2022

Flow cytometry is a well-established analytical technique that has been supporting reliable diagnostics and groundbreaking research for decades. A major breakthrough in the technology was the development of biologically active fluorescent reagents that could be detected by the instruments. Overview, evolution, trends .

Reagent 52

Reagent Antibody Drugs Protein 52

The Pharma Data

DECEMBER 2, 2020

Howard Mayer, Ipsen’s head of research and development, called the Fast Track designation for Onivyde “an extension of Ipsen’s focus and contribution” to the oncology landscape. The license from ERS Genomics now enables Vivlion to offer both R&D reagents and screening services to its customers worldwide. in Mainland China.

Drugs 52

Drugs Gene Editing Genome Genomics 52

Drug Discovery World

MARCH 13, 2023

Between the 24 therapies already approved by the FDA 1 and a marked increase in clinical trials, widespread accessibility to precision medicine feels within reach. Before 2019, CGT drug developers still had a young, academic mindset, ordering reagents, materials, and equipment haphazardly and assuming they would show up when needed.

Gene Therapy 52

Gene Therapy Gene Manufacturing Development 52

FDA Law Blog

AUGUST 3, 2022

If anything, the announcement was remarkably inconspicuous: a seemingly throwaway sentence in a draft compliance policy guide for research use only and investigational use only products. Tests created by labs were important in 1992, but they play a far more vital role in medicine today.

In-Vitro 98

In-Vitro Regulation Compliance Production 98

Drug Discovery World

JULY 18, 2023

Rolf Turk , Senior Manager, Genomics Medicine at Integrated DNA Technologies, examines how CRISPR is being used to enhance cancer therapies. Years of development and fast-paced research have continued to unlock its potential, expanding how CRISPR can be used to treat, detect, and prevent common diseases such as cancer and Covid-19.

DNA 98

DNA Genome Genomics RNA 98

XTalks

OCTOBER 1, 2020

WeiQi Lin, MD, PhD, executive vice president of research & development and principal scientist, DURECT Corporation. Lin has made several transitions throughout her career, from being a clinician at an academic center, to academic research, to heading business development in industry. Motivations for Transition.

Scientist 52

Scientist In-Vitro Research Life Science 52

Drug Discovery World

JUNE 6, 2023

Philip D Greenberg Dr Greenberg is the Rona Jaffe Foundation Endowed Chair and professor and head of the Program in Immunology, Clinical Research Division, at Fred Hutchinson Cancer Center. He is also a professor of medicine and immunology at the University of Washington School of Medicine.

Protein 52

Protein DNA RNA Research 52

Drug Discovery World

DECEMBER 15, 2022

As gene editing technologies like CRISPR progress toward clinical study, researchers must continue to advance new approaches and address inherent challenges, explains Jon Chesnut, PhD, Senior Director, Cell Biology R&D, Thermo Fisher Scientific. Topping the list of alternatives are lipid nanoparticles (LNPs) and electroporation.

Gene Editing 52

Gene Editing Gene In-Vivo Genome 52

Drug Discovery World

JUNE 14, 2023

Blood and stem cell donors are often also willing to provide products for ethically approved research and development. They said: “These therapies are complex and time consuming to manufacture, and the success of the medicine relies on a robust, reliable, and safe manufacturing process.

Manufacturing 52

Manufacturing Production Gene Therapy Development 52

Drug Discovery World

OCTOBER 20, 2022

This panel can be applied to other cancers or modified to better fit researchers’ or clinicians’ needs. Panels like these will be the future of personalised medicine as we will be able to examine the immune environment inside a tumour, response to checkpoint inhibitors, CAF population heterogeneity, and cell proliferation.

Antibody 52

Antibody In-Vivo Life Science Development 52

The Pharma Data

DECEMBER 23, 2020

The agreement includes a £500,000 upfront payment to Avacta which gives Astrea the rights to generate and develop Affimer reagents in-house for affinity separation. BioNTech – Germany’s BioNTech and partner Pfizer secured authorization from the European Medicines Agency for its COVID-19 vaccine. It is a division of Gamma Biosciences.

Drugs 52

Drugs Licensing Licensing Vaccination 52

Drug Discovery World

OCTOBER 14, 2022

HTS is widely used by pharmaceutical companies to identify compounds (or ‘hits’) that show pharmacological activity, which are used as starting points to optimise medicines during the drug discovery process. HTS as a tool for drug discovery has evolved rapidly since the origin of the technique in the 1990s. Elsen and J.D. McLaren, V.

Drugs 52

Drugs In-Vitro Development Production 52